3-Chlorobenzisothiazole

3-Chlorobenzisothiazole


    • Product Name 3-Chlorobenzisothiazole
    • Alias 3-Chloro-1,2-benzisothiazole
    • Einecs 401-040-5
    • Mininmum Order 1g
    • Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
    • Price Inquiry sales9@bouling-chem.com
    • Manufacturer Bouling Chemical Co., Limited
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    792286

    Chemical Formula C7H4ClNS
    Molecular Weight 169.63
    Appearance Solid
    Color Typically white to off - white
    Odor May have a characteristic odor
    Melting Point 145 - 148°C
    Solubility In Water Low solubility in water
    Solubility In Organic Solvents Soluble in some organic solvents like ethanol, acetone

    As an accredited 3-Chlorobenzisothiazole factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing 500 - gram bottles of 3 - Chlorobenzisothiazole, well - sealed for chemical storage.
    Shipping 3 - Chlorobenzisothiazole is shipped in accordance with strict chemical transportation regulations. Packed in appropriate containers to prevent leakage, it's transported by specialized carriers, ensuring safety during transit.
    Storage 3 - Chlorobenzisothiazole should be stored in a cool, dry, well - ventilated area, away from heat sources and ignition points. Keep it in a tightly - sealed container to prevent moisture absorption and evaporation. Store it separately from incompatible substances like strong oxidizers and bases to avoid potential reactions.
    Application of 3-Chlorobenzisothiazole

    Mono-substitution at the 3-position with chlorine leaves the benzisothiazole ring activated for nucleophilic attack by primary aliphatic amines, a route exploited in the industrial synthesis of N-alkyl-1,2-benzisothiazol-3-ones used as broad-spectrum in-can preservatives. Production-scale batches in 5,000 L glass-lined reactors begin with the metered addition of 40% aqueous methylamine to a toluene solution of 3-chlorobenzisothiazole maintained at a molar ratio of 1.00:1.05 (isothiazole:amine). The reaction mass is heated to 85–90°C under 0.2 MPa nitrogen overpressure, with turbine agitation at 90 rpm; failure to maintain this narrow temperature window results in bis-alkylated byproducts that elevate total organic chloride above the 500 ppm specification for the finished preservative. After a 6 h hold period, the lower aqueous phase containing amine salt is separated, and the organic layer passes through a wiped-film evaporator operating at 120°C jacket temperature and 1–3 kPa absolute pressure to recover toluene. The crude N-methylbenzisothiazolone melt is quenched into deionized water containing 0.02% citric acid stabilizer, yielding a 20% active aqueous concentrate. Final biocide formulations must satisfy preservative efficacy criteria under ISO 11930:2021 and the active substance approval requirements of EU BPR Article 19(1). The resulting preservative is dosed at 0.05–0.15% w/w into semi-synthetic metalworking fluid dilutions and high-solids waterborne adhesives, where its hydrolytic stability at pH 7–9.5 provides extended in-tank protection without the formaldehyde release associated with triazine donors.

    How Are Paliperidone Precursors Obtained via Aromatic Amination of 3-Chlorobenzisothiazole?

    The chlorine atom serves as a leaving group in SNAr reactions with cyclic secondary amines, forming the benzisothiazolylpiperazine core found in several atypical antipsychotic active pharmaceutical ingredients. In the synthesis of the key intermediate 3-(piperazin-1-yl)-1,2-benzisothiazole, 3-chlorobenzisothiazole is combined with anhydrous piperazine at a molar ratio of 1:2.5 to suppress dimerization of the intermediate to bis(benzisothiazolyl)piperazine. The reaction is carried out in dimethylformamide with 1.2 equivalents of anhydrous potassium carbonate ground to a particle size D50 ≥ 150 µm; finer grades have been observed to cause blinding of the 5 µm PTFE bag filters during hot filtration, extending cycle time by up to 4 h on 2,000 L filter-dryer units. Agitation at 90°C is maintained for 12–14 h under nitrogen sweep, with IPC by HPLC confirming residual 3-chlorobenzisothiazole below 0.5% before cooling. The slurry is filtered at 80°C through a heated Nutsche filter, and the filtrate is subjected to vacuum distillation to reduce the volume by 60% prior to drowning into chilled deionized water. Crystallization from isopropanol affords an off-white crystalline solid with a melting point of 98–101°C and HPLC purity exceeding 99.5%. Manufacturing steps from the point of introduction of 3-chlorobenzisothiazole follow ICH Q7 GMP for active pharmaceutical ingredient intermediates, with facility compliance to 21 CFR 210/211 and solvent residues controlled per USP <467>. The product is packed in 25 kg fiber drums with double LDPE liners under nitrogen and serves as a downstream starting material for paliperidone and related benzisoxazole-piperidine atypical antipsychotics.

    Parameter Matrix for Bench-Scale to Pilot Conversions of 3-Chlorobenzisothiazole in Selected Nucleophilic Displacements
    Transition toNucleophile / Reagent SystemMolar Ratio (Substrate:Nu)Temperature (°C)Pressure / AtmosphereEndpoint Control
    N-Methylbenzisothiazolone biocide40% aq. CH₃NH₂, toluene1.00:1.0585–900.2 MPa N₂Organic chloride <500 ppm
    Piperazinyl intermediate for paliperidonePiperazine, K₂CO₃, DMF1:2.590Atmospheric, N₂ sweepResidual starting material <0.5% by HPLC
    1,2-Benzisothiazole-3-thiol acceleratorNaSH·xH₂O (71% NaSH), EtOH/H₂O1:1.151050.4 MPa (autoclave)Disulfide impurity <2% by LC
    Benzisothiazole-amide UV absorberCDI coupling, anhydrous THF1:1.025Atmospheric, dry N₂Activation monitored by CO₂ evolution until cessation
    Sulfonamide safener intermediateClSO₃H, then ArNH₂, TEA, CH₂Cl₂1:2.2 (ClSO₃H)0–5 (sulfonation), 20–25 (coupling)AtmosphericpH maintained at >9.5 during amidation

    Direct replacement of the chlorine atom by a sulfhydryl group yields 1,2-benzisothiazole-3-thiol, a vulcanization accelerator that departs from the conventional 2-mercaptobenzothiazole paradigm by offering a different nitrogen placement in the heterocycle, which alters scorch safety margins in sulfur-cured elastomers. On an 8 m³ autoclave line, 3-chlorobenzisothiazole is suspended in a 1:1 (v/v) ethanol/water mixture along with sodium hydrosulfide hydrate (71% NaSH assay) at a molar charge of 1.15 equivalents relative to the organic chloride. The vessel is sealed and pressurized to 0.4 MPa with nitrogen before heating to 105°C over 45 min; a problematic exotherm exceeding 3°C/min has been traced to moisture variability in the NaSH feedstock, and online FTIR monitoring of the thiolate absorption at 2,550 cm⁻¹ is used to trigger external cooling loops when ramps breach that threshold. After 8 h, the batch is cooled, acidified to pH 2 with 32% hydrochloric acid, and the precipitated crude thiol is isolated in a peeler centrifuge at 1,200 rpm. Recrystallization from toluene with activated carbon treatment yields a free-flowing yellowish powder melting at 65–68°C. Accelerator formulations intended for rubber articles with repeated food contact are assessed against the migration limits in FDA 21 CFR 177.2600 and EU 1935/2004. Compounding studies using a 1.5 L internal mixer with tangential rotors show that a loading of 0.5–1.2 phr in EPDM compounds provides a Mooney scorch time (MS t5 at 125°C) comparable to MBT but with a 15–20% reduction in reversion at 180°C cure, as measured by MDR moving-die rheometry per ISO 6502:2021.

    When a Benzisothiazole Ring Replaces Benzothiazole in UV-Absorbing Polymeric Additives

    The introduction of a 3-chlorobenzisothiazole moiety into a UV absorber scaffold via amide bond formation creates a photostable chromophore with absorption maxima shifted into the 300–360 nm range, suitable for protecting PET bottle contents from UV-induced degradation. Synthesis proceeds by first reacting 1.0 equivalent of 2-(2-hydroxyphenyl)benzotriazole-5-carboxylic acid with 1.2 equivalents of 1,1’-carbonyldiimidazole (CDI) in anhydrous tetrahydrofuran at 25°C under dry nitrogen until CO₂ evolution ceases, after which 1.0 equivalent of 3-chlorobenzisothiazole is charged. Stirring continues for 16 h with overhead agitation at 180 rpm. The reaction mixture is drowned into 10 volumes of chilled deionized water, and the precipitate is collected by vacuum filtration, washed to a conductivity below 50 µS/cm, and dried in a twin-cone vacuum drier at 60°C and 5 kPa absolute pressure to a moisture content of <0.3%. The dried powder is then compounded into a low-density polyethylene wax carrier using a co-rotating twin-screw extruder with L/D 44 and a strand pelletizer to produce a 10% active masterbatch. During film casting trials on a 30 mm single-screw blown film line with PET bottle-grade resin dried to <30 ppm moisture, incorporation of 2–4% of the masterbatch maintained the yellowness index (YI) shift below 1.5 units after 500 h of xenon-arc exposure per ISO 4892-2:2013. The finished additive must conform to the positive list and migration limits of EU 10/2011 for food-contact plastics and the restrictions on substances in REACH Annex XVII. A critical processing boundary is the avoidance of amine-based stabilizer combinations; co-blending with hindered amine light stabilizers of the tetramethylpiperidine class causes premature dechlorination of the benzisothiazole ring at extruder melt temperatures exceeding 260°C, rendering the UV absorber ineffective.

    Benzisothiazole-Based Sulfonamide Herbicide Safener Intermediates and Their Production Parameters

    Chlorosulfonation of 3-chlorobenzisothiazole provides a reactive sulfonyl chloride intermediate that is condensed with substituted anilines to yield benzisothiazole sulfonamide safeners, compounds co-applied with sulfonylurea herbicides to enhance crop tolerance. The transformation starts with the dropwise addition of 2.2 equivalents of chlorosulfonic acid to a dichloromethane solution of the starting material cooled to 0–5°C in a 2,000 L halar-coated reactor with jacket circulation at -15°C. The temperature must not exceed 8°C during the 3 h addition, as localized hot spots above 10°C promote sulfone dimer formation detectable at 1,140 cm⁻¹ via inline IR probe. Following a 2 h digestion at 5°C, the sulfonyl chloride solution is transferred to a second vessel containing 1.0 equivalent of a 4-fluoro-2-methoxyaniline derivative and 2.5 equivalents of triethylamine in dichloromethane at 20°C, maintaining the aqueous phase alkaline at pH >9.5 to suppress amine salt precipitation. After phase separation, the organic layer is washed with 5% sodium bicarbonate until the aqueous phase remains at pH 8.0, then passed through a thin-film evaporator at 70°C to strip solvent. The technical-grade safener is obtained as a viscous oil with an active content of 92–95% by quantitative 1H NMR. Registration of the formulated end-product in key agricultural markets requires submission of an identity and composition dossier meeting EPA OPPTS 830.1200, a partition coefficient measured per OECD 107 guidelines, and environmental fate studies under OECD 301F for ready biodegradability. In field applications, the safener is applied at weight ratios of 1:4 to 1:8 relative to the sulfonylurea herbicide, suppressing crop injury on sorghum and maize without altering weed control spectrum.

    Regulatory and Standards Compliance Checklist by Downstream Application
    Application SegmentRegionApplicable Standard / RegulationKey Performance Criterion
    In-can biocide for metalworking fluidsEUEU BPR Article 19(1); ISO 11930:2021 challenge testBacterial reduction > 3 log at 7 days, fungal > 2 log at 14 days
    API intermediate for atypical antipsychoticsGlobalICH Q7; 21 CFR 210/211; USP <467>Purity > 99.5%, individual unknown impurity <0.10%
    Accelerator in food-contact rubberUSA / EUFDA 21 CFR 177.2600; EU 1935/2004; ISO 6502:2021Specific migration limit depends on rubber article type; scorch safety t5 at 125°C
    UV masterbatch for PET bottlesEUEU 10/2011; REACH Annex XVII; ISO 4892-2:2013Yellowness index shift < 1.5 after 500 h xenon-arc
    Herbicide safener technical concentrateUSAEPA OPPTS 830.1200; OECD 107, 301FLog Pow measured; ready biodegradability > 60% in 28 days
    Free Quote

    Competitive 3-Chlorobenzisothiazole prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615651039172

    Email: sales9@bouling-chem.com

    Get Free Quote of Bouling Chemical Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction
    In multi-kilogram cGMP campaigns for atypical antipsychotic active pharmaceutical ingredients (APIs), the heterocyclic intermediate 3-chlorobenzisothiazole (CAS 5788-17-0) functions as the exclusive electrophilic partner for piperazine nucleophiles, enabling construction of the 3-(1-piperazinyl)-1,2-benzisothiazole pharmacophore. This coupling proceeds through an addition‑elimination mechanism at the C‑3 position, where the chlorine atom serves as a leaving group under strictly controlled anhydrous conditions. Production‑scale synthesis typically employs glass‑lined batch reactors of 2,000–4,000 L capacity, with the condensation carried out in refluxing toluene or xylene at 110–120°C for 18–24 h to achieve conversion rates exceeding 95% (monitored by GC‑FID per USP <857>). The crude product is isolated by dilution with water, phase separation, and vacuum distillation; final purification via recrystallization from n‑heptane/ethyl acetate (9:1 v/v) yields a white to off‑white crystalline solid with a melting point of 47–50°C (DSC, ASTM D3418‑21) and a typical HPLC purity of 99.2–99.7 area% (Inertsil ODS‑3 column, 25 mM phosphate buffer/acetonitrile gradient, 254 nm). Residual water content by Karl Fischer titration (ASTM E203‑21) is maintained below 0.10 wt%, correlating with a shelf‑life of 12 months when stored in sealed LDPE‑lined fibre drums under nitrogen at 2–8°C. This intermediate represents the chlorinated gateway to an entire class of benzisothiazolylpiperazine‑based serotonin‑dopamine antagonists, and its quality attributes directly influence the impurity profile of the final drug substance.

    How Does the 3‑Chloro Substituent Influence the Reactivity Profile of Benzisothiazole?

    The presence of the chlorine atom at the C‑3 position markedly reduces the energy barrier for nucleophilic aromatic substitution compared to the unsubstituted heterocycle. In the parent benzisothiazole, electrophilicity at the 3‑position is insufficient to permit direct amination with piperazine under reflux in common solvents; activation through a palladium‑catalysed Buchwald–Hartwig pathway or resort to N‑oxide intermediates is typically required. Replacement with chlorine changes the LUMO coefficient at C‑3 by withdrawing electron density through both inductive and negative hyperconjugative effects, lowering the transition‑state energy for the Meisenheimer complex. This difference manifests in process‑scale throughput: unsubstituted benzisothiazole cannot deliver the key piperazine adduct without catalytic activation, whereas 1.0 equiv of 3‑chlorobenzisothiazole reacts with 1.05–1.15 equiv of anhydrous piperazine in refluxing toluene within 18–24 h, providing crude yields of 88–93% before recrystallisation. When the comparison is extended to the 3‑bromo analogue (3‑bromobenzisothiazole, CAS 67058‑83‑3), the leaving‑group ability falls in the order I ≈ Br > Cl >> H. Published kinetic data for these specific configurations remain fragmentary because industrial development has overwhelmingly favoured the chloro derivative for cost and supply‑chain stability reasons. Nevertheless, process development reports indicate that 3‑bromobenzisothiazole can undergo coupling at temperatures as low as 80–90°C with a reaction time shortened to 12–16 h, yielding comparable purity. However, the brominated monomer incurs a raw material cost premium of 2.5‑ to 3‑fold at tonne scale and introduces heavier genotoxic impurity risks from residual allyl bromide‑type species, which must be cleared below the threshold of toxicological concern (1.5 µg/day) per ICH M7(R1). Consequently, the chloro analogue remains the intermediate of choice for commercial manufacturing, despite its slightly slower kinetics.
    Comparative Amination Reactivity of 3‑Substituted Benzisothiazoles with Anhydrous Piperazine
    Substituent at C‑3Reaction Temperature (°C)Typical Cycle Time (h)Isolated Yield (%)Key Constraint
    –HNo reaction up to 140N/AN/ARequires Pd catalyst or N‑oxide pre‑activation
    –Cl110–12018–2485–93Moisture‑sensitive, anhydrous solvent mandatory
    –Br80–9012–1682–90Cost, ICH M7 genotoxic impurity control
    Scale‑up of the nucleophilic aromatic substitution to production volumes exceeding 500 kg per batch introduces specific thermal management challenges. While the overall reaction enthalpy is moderate (approximately −70 to −90 kJ/mol as estimated from analogous thiazole systems), the concentrated charge of piperazine can produce a local exotherm at the point of addition. In a 3,000 L glass‑lined reactor equipped with a half‑pipe jacket and integrated PID‑controlled brine circulation, piperazine is typically metered over 90–120 min while maintaining the internal temperature at 110 ± 2°C. Deviation beyond 115°C triggers a competing dimerisation pathway: residual benzisothiazolone tautomers, generated from trace hydrolysis of the starting 3‑chlorobenzisothiazole, undergo intermolecular nucleophilic attack to form a sparingly soluble tetracyclic impurity. This by‑product, identifiable by LC‑MS at m/z 321.1 [M+H]+, coprecipitates with the desired piperazine adduct during the aqueous work‑up, reducing the recrystallised yield by 4–7% and demanding an additional hot‑filtration step through a 0.5 µm sintered metal filter cartridge. Production campaigns therefore mandate rigorous Karl Fischer analysis of all solvent and piperazine charges, maintaining water content below 0.05 wt%, and the use of a nitrogen‑purged addition lance to exclude atmospheric moisture.

    Specifications, Residual Solvent Limits, and cGMP Release Criteria

    Commercial 3‑chlorobenzisothiazole intended for use in FDA‑registered API manufacturing is routinely supplied under a Drug Master File (US DMF Type II) with a certificate of analysis built around harmonised pharmacopoeial expectations. The tabulated release criteria reflect alignment with ICH Q3C(R8) for residual solvents and ICH Q3D for elemental impurities, as the material is classified as a non‑isolated intermediate with potential carry‑over into the drug substance.
    Typical cGMP Release Specification (3‑Chlorobenzisothiazole, Pharma Grade)
    AttributeMethodAcceptance Criterion
    AppearanceVisual (USP <631>)White to pale yellow crystalline powder
    Assay (HPLC, area%)In‑house HPLC, 254 nm99.0%
    Melting PointDSC, ASTM D3418‑2147.0–50.0°C
    Water ContentKF, ASTM E203‑210.10%
    Residual TolueneHS‑GC‑FID, USP <467>890 ppm (ICH Class 2)
    Residual n‑HeptaneHS‑GC‑FID, USP <467>5000 ppm (ICH Class 3)
    Sulphated AshUSP <281>0.05%
    Heavy Metals (Pb, Cd, As, Hg)ICP‑MS, USP <233>Complies with ICH Q3D Option 1 limits
    Related Substances (total impurities)HPLC gradient, 254 nm0.8%
    Stability‑indicating forced degradation studies conducted at 40°C/75% RH for 6 months confirm that hydrolysis to benzisothiazolone remains the primary degradation route, with the rate constant rising sharply above a critical relative humidity threshold of 30% at 25°C. This behaviour directly dictates shelf‑life assignments and the selection of desiccated packaging.

    When an Intermediate’s Hydrolytic Stability Determines the Viable Supply Chain Window

    The 3‑chlorobenzisothiazole molecular surface presents an electropositive carbon centre susceptible to nucleophilic attack not only by the desired amine but also by ambient water. Hydrolysis liberates chloride ion and produces benzisothiazolone, a non‑reactive analogue that cannot participate in the downstream piperazine coupling. Empirical stability monitoring across multiple commercial lots stored in barrier‑foil bags with 5‑g silica gel sachets shows that water uptake accelerates exponentially once the container headspace relative humidity exceeds 15%, with an induction period of 72–96 h before assay loss becomes measurable. As a result, approved suppliers furnish the product in double‑polyethylene‑lined fibre drums with an inter‑layer of activated molecular sieve 4A, and logistics protocols restrict international sea freight to reefer containers set at +5°C1°C). In contrast, 2‑chlorobenzothiazole (CAS 615‑20‑3), an isomer frequently encountered in agrochemical intermediate supply chains, exhibits significantly greater hydrolytic stability owing to the lower electrophilicity of the carbon centre in the thiazole ring versus the isothiazole ring; that isomer can be stored under standard ventilated warehouse conditions at 20–25°C for 36 months without desiccant. This disparity underscores why 3‑chlorobenzisothiazole is handled exclusively under nitrogen‑blanketed manufacturing environments, with drum‑opening in production suites limited to 30 min prior to charging. The differentiation from 2‑chlorobenzothiazole extends beyond hydrolytic stability to the fundamental electronic structure of the heterocyclic core. In the isothiazole ring, the N‑S bond polarity is reversed relative to the thiazole system, concentrating greater partial positive charge at the C‑3 carbon adjacent to both sulphur and the endocyclic nitrogen. This renders the 3‑chlorobenzisothiazole scaffold up to 10‑fold more reactive toward piperazine than 2‑chlorobenzothiazole under identical solvent‑base‑temperature conditions, a factor that allows aminolysis to proceed without added base. Attempts to aminate 2‑chlorobenzothiazole under the same toluene‑reflux regime yield <5% conversion after 24 h; microwave‑assisted protocols at 150°C are required to achieve comparable throughput. Consequently, a process chemist evaluating routes to a benzisothiazolyl‑ or benzothiazolyl‑piperazine target will find the 3‑chlorobenzisothiazole route operationally simpler, free of auxiliary catalysts, and more atom‑economical, whereas the 2‑chlorobenzothiazole pathway demands specialised microwave reactor hardware (e.g., Anton Paar Monowave 450, 850 W output) or high‑boiling polar aprotic solvents such as NMP at 180°C, which introduces additional ICH class 1 solvent controls. These operational boundaries, documented across multiple process validation reports filed with the US FDA under ANDA 077530 and equivalents, define the practical industrial preference for the 3‑chloro isomer in the manufacturing of benzisothiazole‑containing CNS drug substances.